European gram negative antibacterial engine

  • Description
  • Details
  • Subprojects
  • History
  • Publications
  • Patents
  • Trials
Project Title: European gram negative antibacterial engine
Project Number: CORDIS-203716
Project web address: Follow on CORDIS
 
Project Description:
The intensive use and misuse of antibiotics has resulted in some level of antibiotic resistance in essentially all human bacterial pathogens. There is a growing concern that the loss of therapeutic options will present us with a post-antibiotic era where present and future medical advances are negated. Resistant bacteria dramatically reduce the possibilities of treating infections effectively, and drastically increase the risk of complications with a fatal outcome. Antimicrobial resistance, however, is an unavoidable consequence of antibiotic use and therefore new, effective antibacterials will always be needed and once developed should be used carefully, avoiding the overuse which can drive resistance. Despite the recognized need for new antimicrobials for clinical use, the reality is that only two new classes of antibiotics have been brought to market in the last 30 years and many drug developers have left the field. This urgency is especially true when considering resistant Gram-negative infections where carbapenem-resistance is rising and use of drugs of last resort, such as colistin, is increasing. The New Drugs 4 Bad Bugs (ND4BB) initiative is a series of programmes designed to directly address some of the scientific challenges associated with antibacterial drug discovery and development. The ND4BB ENABLE consortium will meet the challenges ahead by creating and optimising a portfolio of new antibiotics ranging from Hits through Phase 1 clinical studies.The overarching goals of the ENABLE consortium are to: 1) create a drug discovery platform with the expertise and resource base to prosecute multiple antibacterial programmes in parallel; and 2) increase the overall pipeline in the antibacterial area by applying this platform to optimise a variety of antibacterial programmes. More specifically the key objectives of the consortium are designed to increase the overall pipeline of high quality, novel mode of action medicines to treat serious systemic Gram-negative infections by identifying three antibacterial Leads, two antibacterial Candidates and progressing at least one compound into preclinical and Phase 1 clinical studies.The platform group is made up of academics and SMEs from across Europe with the diverse expertise including from clinical microbiology, in vivo pharmacology, computational and medicinal chemistry, ADME profiling, PKPD modelling, pharmaceutics, assay development and screening all needed to undertake this programme. This group, coupled with additional expertise and advice from within the EFPIA partners, will bring an unrivalled focus and breadth of judgment to this important area of research. The programmes are coming from institutions across Europe, initially with seven efforts from public partners, and arising from a novel discovery stage alliance between GSK and Sanofi. These initial programmes to be considered for ENABLE cover a diverse landscape of targets and approaches including natural products, PNA-peptides, synthetic small molecules, and follow ups / improvements to medicines already available. In addition, soon after initiation, ENABLE will launch an open call for additional efforts to create a sustainable portfolio of antibacterial discovery programmes moving forward. The ENABLE consortium will provide a unique opportunity for a productive collaboration between leading European academic researchers, SMEs and the pharmaceutical industry. We believe these interactions will be synergistic for everyone concerned. Bringing together different disciplines for the common goals outlined in this proposal will make Europe the world-leader in antimicrobial drug discovery. The creation of a cooperative environment in the lifetime of this project and beyond will fulfill the needs of European society in the battle against antibiotic resistance and make a sustainable impact on the future of antibacterial drug discovery.
 
Project Terms:
There are no related terms in database.
Project Title: European gram negative antibacterial engine
Project Number: CORDIS-203716
Project web address: Follow on CORDIS
Organization: Glaxosmithkline Research And Development Limited, United Kingdom, Stevenage
Collaborators: Uppsala University, SE
University Of Zurich, CH
Cardiff University, GB
Universite De Liege, BE
Kobenhavns Universitet, DK
Aston University, GB
The Chancellor, Masters And Scholars Of The University Of Oxford, GB
John Innes Centre, GB
Universitat De Barcelona, ES
St George'S Hospital Medical School, GB
Helsingin Yliopisto, FI
Astra Zeneca Ab, SE
Servicio Madrileno De Salud, ES
Agencia Estatal Consejo Superior De Investigaciones Cientificas, ES
Region Hovedstaden, DK
Latvijas Organiskas Sintezes Instituts, LV
Beactica Ab, SE
Sanofi-Aventis Recherche & Developpement, FR
National Medicines Institute (Narodowy Instytut Lekow), PL
Biomol-Informatics Sl, ES
Helperby Therapeutics Ltd, GB
Stichting Vu, NL
Fundación Centro De Excelencia En Investigación De Medicamentos Innovadores En Andalucia Medina, ES
Sp Process Development, SE
Molecular Discovery Ltd, GB
Ot Chemistry, SE
Basilea Pharmaceutica International Ag, CH
Northern Antibiotics Oy, FI
European Biotechnology Network Aisbl, BE
Bioresources Technology & Engineering Gmbh, DE
The Research Network Ltd., GB
Nosopharm Sas, FR
Mps Hamburg Gmbh, DE
Spero Europe Limited, GB
Redx Pharma Ltd, GB
Inspiralis Ltd, GB
Juvabis Gmbh, CH
Keytolead Ab, SE
Asclepia Outsourcing Solutions Bvba, BE
Principal Investigators (PI): Mary Anderson, GB
Isabelle Halleux, BE
Xavier Gutierrez, ES
Per Källblad, SE
Tiina Berg, FI
Eva Lindgren, SE
Dace Karkle, LV
Yvonne Kops, NL
Gill Wells, GB
José Ignacio Flores Nicolás, ES
Jane Boland, GB
Christine Svärd, SE
Diego Pozas, ES
Paulino Gómez-Puertas, ES
Klaus Tofting, DK
Fredrik Lehmann, SE
Karen Woodhall, GB
Keith Sexton, GB
Laurenz Kellenberger, CH
Robert Stavenger, GB
Renata Cellmar, PL
Timo Vaara, FI
Olivier Brun, FR
Maríaángeles López Vázquez, ES
Heike Kempas, BE
Anna Lobell, SE
Daniela Mueller, DE
Andrew Brian Mcelroy, GB
Karsten Fey Kristiansen, DK
Ann Savell, GB
Philippe Villain-Guillot, FR
Christa Möhring, DE
Andrea Wagner, CH
Steve Garbacz, GB
Stephen Smith, GB
Alison Howells, GB
Gunter Festel, CH
Martin Bohl, GB
Jan Blid, SE
Frederik Deroose, BE
 
Project Categories:
Natural Sciences
 
Other Information:
Fiscal Year: 2014
Project Start Date: 1 February 2014
Project End Date: 31 January 2020
Project program: FP7-JTI
 
Project Funding Information:
Funding Mechanism: JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)
Year Funding Organization Total Funding, $
2014 European Research Council $97,476,860
Project Title: European gram negative antibacterial engine
Project Number: CORDIS-203716
Project web address: Follow on CORDIS
 
Title FY Funding
There are no results for this project in database.
Project Title: European gram negative antibacterial engine
Project Number: CORDIS-203716
Project web address: Follow on CORDIS
 
Project Title Organization FY Funding
European Gram Negative Antibacterial EngineGlaxosmithkline Research And Development Limited2014$97,476,860
Project Title: European gram negative antibacterial engine
Project Number: CORDIS-203716
Project web address: Follow on CORDIS
 
Title Journal Year Country Rel
Project Title: European gram negative antibacterial engine
Project Number: CORDIS-203716
Project web address: Follow on CORDIS
 
Title Year
Project Title: European gram negative antibacterial engine
Project Number: CORDIS-203716
Project web address: Follow on CORDIS
 
Title Phase Year